A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)
Latest Information Update: 12 Apr 2024
At a glance
- Drugs Enfortumab vedotin (Primary) ; Pembrolizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-B15; KEYNOTE-B15 / EV-304
- Sponsors Merck Sharp & Dohme Corp.
- 17 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 18 Feb 2023 Trial design presented at the 2023 Genitourinary Cancers Symposium
- 17 Feb 2023 Planned End Date changed from 23 Jun 2026 to 23 Dec 2026.